Wall Street brokerages expect AmerisourceBergen Corp. (NYSE:ABC) to announce $1.56 earnings per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for AmerisourceBergen’s earnings, with the highest EPS estimate coming in at $1.60 and the lowest estimate coming in at $1.48. AmerisourceBergen reported earnings of $1.45 per share during the same quarter last year, which would indicate a positive year over year growth rate of 7.6%. The firm is expected to announce its next quarterly earnings report on Tuesday, November 5th.

According to Zacks, analysts expect that AmerisourceBergen will report full-year earnings of $7.05 per share for the current year, with EPS estimates ranging from $7.03 to $7.08. For the next year, analysts expect that the firm will report earnings of $7.54 per share, with EPS estimates ranging from $7.21 to $7.70. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover AmerisourceBergen.

AmerisourceBergen (NYSE:ABC) last posted its earnings results on Thursday, August 1st. The company reported $1.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.62 by $0.14. AmerisourceBergen had a net margin of 0.54% and a return on equity of 47.88%. The firm had revenue of $45.24 billion during the quarter, compared to analyst estimates of $45.15 billion. During the same quarter in the prior year, the business posted $1.54 EPS. The business’s revenue was up 4.9% compared to the same quarter last year.

ABC has been the subject of several recent analyst reports. Argus reduced their target price on shares of AmerisourceBergen from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, June 3rd. ValuEngine lowered shares of AmerisourceBergen from a “hold” rating to a “sell” rating in a research note on Tuesday, August 6th. TheStreet upgraded shares of AmerisourceBergen from a “c+” rating to a “b” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research upgraded shares of AmerisourceBergen from a “hold” rating to a “buy” rating and set a $89.00 target price for the company in a research note on Wednesday, June 12th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $88.00.

Shares of NYSE ABC traded up $1.77 during trading on Thursday, hitting $87.34. The stock had a trading volume of 811,800 shares, compared to its average volume of 1,393,464. AmerisourceBergen has a 12 month low of $69.36 and a 12 month high of $94.85. The company has a debt-to-equity ratio of 1.40, a current ratio of 0.95 and a quick ratio of 0.56. The company has a market capitalization of $18.07 billion, a PE ratio of 13.46, a PEG ratio of 1.54 and a beta of 0.97. The firm has a fifty day moving average of $87.43 and a two-hundred day moving average of $82.00.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Monday, August 19th will be given a dividend of $0.40 per share. The ex-dividend date is Friday, August 16th. This represents a $1.60 annualized dividend and a yield of 1.83%. AmerisourceBergen’s payout ratio is currently 24.65%.

In related news, insider John G. Chou sold 13,997 shares of the stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $89.58, for a total transaction of $1,253,851.26. Following the completion of the transaction, the insider now owns 65,782 shares in the company, valued at $5,892,751.56. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Steven H. Collis sold 19,905 shares of the stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $89.58, for a total transaction of $1,783,089.90. Following the transaction, the chief executive officer now owns 154,484 shares of the company’s stock, valued at approximately $13,838,676.72. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 191,379 shares of company stock valued at $16,502,190. 27.80% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in AmerisourceBergen by 16.8% during the second quarter. Vanguard Group Inc. now owns 18,910,594 shares of the company’s stock valued at $1,612,318,000 after purchasing an additional 2,719,868 shares during the last quarter. Boston Partners lifted its holdings in AmerisourceBergen by 222.4% during the first quarter. Boston Partners now owns 2,343,027 shares of the company’s stock valued at $186,317,000 after purchasing an additional 1,616,201 shares during the last quarter. Marshall Wace North America L.P. lifted its holdings in AmerisourceBergen by 318.9% during the first quarter. Marshall Wace North America L.P. now owns 907,474 shares of the company’s stock valued at $72,163,000 after purchasing an additional 690,823 shares during the last quarter. Amundi Pioneer Asset Management Inc. lifted its holdings in AmerisourceBergen by 493.2% during the second quarter. Amundi Pioneer Asset Management Inc. now owns 757,887 shares of the company’s stock valued at $64,617,000 after purchasing an additional 630,123 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ lifted its holdings in AmerisourceBergen by 1,584.3% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 490,101 shares of the company’s stock valued at $41,786,000 after purchasing an additional 461,002 shares during the last quarter. Institutional investors own 66.03% of the company’s stock.

About AmerisourceBergen

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers.

See Also: How mutual funds make money

Get a free copy of the Zacks research report on AmerisourceBergen (ABC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AmerisourceBergen (NYSE:ABC)

Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.